Minomic Launches Pilot Study of MiStat Novel Prostate Cancer Screening Technology

Minomic Launches Pilot Study of MiStat Novel Prostate Cancer Screening Technology
Australian biomarker discovery company Minomic International Ltd has announced it will launch a U.S. trial of its MiStat™ prostate cancer screening test, with aims of achieving U.S. Food and Drug Administration (FDA) regulatory approval upon completion. MiStat™ technology is an early detection screening assay that can identify the presence of a specific and proprietary biomarker,

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *